Construction of Eukaryotic Expression Plasmid pEGFP- ATP1B1 and Its Effect on Gastric Adenocarcinoma Cell SGC-7901
Zhu-juan XIONG,Ping LIN,Jie ZHANG,Xiu-jie WANG,Qi WANG,Jing-jing REN,Hong-liang YANG,Jing WANG,Ya-ying WU
DOI: https://doi.org/10.3969/j.issn.1672-173X.2008.02.002
2008-01-01
Abstract:Objective To establish the eukaryotic expression plasmid containing the code gene of Na+, K+-ATPase β1-subunit (ATP1B1) and the basis of ATP1B1 applied to antitumor gene therapy. Methods The ATP1B1 cDNA was amplified from leukocyte gene library and then cloned into the eukaryotic expression vector pEGFP-C3. The recombinant plasmid, named as pEGFP-ATP1B1, was determined with restriction enzyme and sequencing analyses. Next pEGFP-ATP1B1 was transferred into gastric adenocarcinoma SGC-7901 cells by lipofectamine, then ATP1B1 mRNA expression in transfected cells was detected by real-time PCR, and also ATPase was detected after cell transfection, as well as the proliferation of such cells was measured by MTT. Results The analysis confirmed that the recombinant pEGFP-ATP1B1 contained the ATP1B1 cDNA. After cell transfection, the expression of ATP1B1 mRNA(129. 2%) and the activity of ATPase [(2. 95±0. 210)%] were higher, and the growth of the SGC-7901 cells transfected with ATP1B1 was inhibited obviously when compared with the control group. Conclusion The recombinant pEGFP-ATP1B1 is constructed successfully, and this recombinant eukaryotic expression vector could be used in additional studies on the biological effect of ATP1B1 and its use in anti-tumor gene therapy.